Lv11
57 积分 2025-03-06 加入
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
4小时前
已完结
慢性鼻窦炎诊断和治疗指南（2024）
22天前
已完结
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
1个月前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
1个月前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
1个月前
已完结
皖公网安备34019202002308
